SR-13668 is an indolocarbazole derivative patented by American nonprofit scientific research institute SRI International as a chemotherapeutic and chemopreventive agent for the treatment and prevention of cancers, such as breast and ovarian cancer. SR-13668 appears to inhibit Akt activation by blocking growth factor-stimulated Akt phosphorylation, and it does not target the ATP substrate binding site. Preclinical safety studies showed that SR-13668 is not genotoxic in Ames mutagenicity tests or in the mouse micronucleus test. In a 14-day toxicity study in which Sprague−Dawley rats have orally dosed with SR13668 no drug-related mortality, changes in body or organ weights, or other signs of significant toxicity were seen at any dose level. However, the compound is highly hydrophobic and its limited oral bioavailability has hindered its clinical translation.